“A STUDY OF EFFICACY AND SAFETY OF TABLET DEFLAZACORT IN PATIENTS WITH NASAL POLYPS ATTENDING A TERTIARY CARE HOSPITAL”
DOI:
https://doi.org/10.22159/ijcpr.2025v17i5.7065Keywords:
Nasal polyps, Deflazacort, Steroid, Adverse drug reactions, EfficacyAbstract
Objective: The aim of this study is to assess the efficacy and safety of the tablet deflazacort in nasal polyps patients and also to assess the causality, severity, and preventability of identified adverse drug reactions.
Methods: Fifty patients with Nasal polyps were treated with Deflazacort. The efficacy of the drug was assessed by SNOT (Sino-nasal outcome test) SCORE at baseline (0), 1st, 2nd w. All the adverse drug reactions (ADRs) due to the study drug was reported in a Suspected Adverse Drug Reaction Reporting form in each follow-up.
Results: After the completion of treatment, symptom scores of all the patients were improved. Of all the patients, 32% showed complete recovery, 50% showed improvement of symptoms, and 18% showed no/little improvement of symptoms. On an average about 82% of patients showed improvement in symptoms.
Conclusion: The efficacy of Deflazacort in the treatment of Nasal polyps is proven in this study. Moreover, less Adverse drug reactions (ADRs) is also reported, which confers it as an optimal treatment choice for Diabetic patients who are requiring steroid therapy.
Downloads
References
1. Georgy MS, Peters AT. Nasal polyps. Allergy Asthma Proc. 2012;33(3):22-3. doi: 10.2500/aap.2012.33.3537.
2. Bhat VS. Steroid therapy for nasal polyp: compliance due to cost and phobia in developing countries. JOENTR. 2018;10(6):312-6. doi: 10.15406/joentr.2018.10.00369.
3. Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc. 1996;17(5):231-6. doi: 10.2500/108854196778662246.
4. Raciborski F, Arcimowicz M, Samolinski B, Pinkas W, Samel Kowalik P, Sliwczynski A. Recorded prevalence of nasal polyps increases with age. PDA. 2020;38(4):682-8. doi: 10.5114/ada.2020.99365.
5. Bonfils P. Medical treatment of paranasal sinus polyposis: a prospective study in 181 patients. Ann Otolaryngol Chir Cervicofac. 1998;115(4):202-14. PMID 9827187.
6. Textbook of diseases of ear nose and throat and head and neck surgery-PL Dhingra, Shruti Dhingra. 7th ed; 2021. p. 196.
7. De Conde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-5. doi: 10.1002/lary.26391, PMID 27859303.
8. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317-33. doi: 10.2165/00003495-199550020-00008, PMID 8521761.
9. Gonzalez Perez O, Luquin S, Garcia Estrada J, Ramos Remus C. Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity. Adv Ther. 2007;24(5):1052-60. doi: 10.1007/BF02877711.
10. Parente L. Deflazacort: therapeutic index relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1. doi: 10.1186/s40360-016-0111-8.
11. Luzzani F, Glasser A. Differential binding in vitro to glucocorticoid receptors of deflazacort and prednisolone. Eur J Pharmacol. 1981;76(4):427-30. doi: 10.1016/0014-2999(81)90115-1.
12. https://melbentgroup.com.au/wpcontent/uploads/2016/10/meg-snot-22-scoring.pdf.
13. https://www.ipc.gov.in/images/adr_reporting_form_1.4_version.pdf.
14. https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
15. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. American Journal of Health System Pharmacy. 1992;49(9):2229-32. doi: 10.1093/ajhp/49.9.2229.
16. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538. PMID 10118597.
17. Toledano Munoz A, Herraiz Puchol C, Navas Molinero C, Garcia Simal M, Navarro Cunchillos M, Galindo Campillo AN. Epidemiological study in patients with nasal polyposis [Epidemiological study in patients with nasal polyposis]. Acta Otorrinolaringol Esp. 2008;59(9):438-43. doi: 10.1016/S0001-6519(08)75115-X, PMID 19080774.
18. Gelardi M, Iannuzzi L, Tafuri S, Passalacqua G, Quaranta N. Allergic and non-allergic rhinitis: relationship with nasal polyposis asthma and family history. Acta Otorhinolaryngol Ital. 2014;34(1):36-41. PMID 24711681.
19. Greisner WA, Settipane GA. Hereditary factor for nasal polyps. Allergy Asthma Proc. 1996;17(5):283-6. doi: 10.2500/108854196778662192, PMID 8922148.
20. Cassano P, Marini F, Indraccolo AS, Curatoli FP. Corticosteroid therapy in the prevention of recurrent post-surgical nasal polyposis. Acta Otorhinolaryngol Ital. 1996;16(4):334-8.
21. Tandon VR, Singh P, Mahajan A, Khajuria V. Comparative adverse drug profile of deflazacort vs conventional corticosteroids in spontaneous reporting system of pharmacovigilance. JK Sci. 2014;16(1):16.
22. Sousa NG, Faria E, Carrapatoso I, Almeida E, Geraldes L, Chieira C. Deflazacort: a possible alternative in corticosteroid allergy. J Investig Allergol Clin Immunol. 2010;20(5):449-51.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.